ZYLOX-TONBRDG.MED.TECH.H1 Cash Flow-to-Debt Ratio
ZYLOX-TONBRDG.MED.TECH.H1 cash flow-to-debt ratio. ZYLOX-TONBRDG.MED.TECH.H1 (818) has a Cash Flow-to-Debt Ratio of 0.50x as of December 2024, meaning its operating cash flow of €174.08 Million could theoretically repay 0% of its total liabilities (€351.56 Million) in one year. Check ZYLOX-TONBRDG.MED.TECH.H1 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of ZYLOX-TONBRDG.MED.TECH.H1 (2021–2024)
Cash flow-to-debt ratio of ZYLOX-TONBRDG.MED.TECH.H1 from 2021 to 2024. Historical debt coverage capacity for ZYLOX-TONBRDG.MED.TECH.H1 across 4 annual periods. Check ZYLOX-TONBRDG.MED.TECH.H1 investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
ZYLOX-TONBRDG.MED.TECH.H1 Cash Flow-to-Debt Ratio by Year (2021–2024)
ZYLOX-TONBRDG.MED.TECH.H1 cash flow-to-debt ratio by year from 2021 to 2024. Year-by-year debt coverage analysis for ZYLOX-TONBRDG.MED.TECH.H1. For the full cash flow conversion analysis, see cash flow conversion of ZYLOX-TONBRDG.MED.TECH.H1.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.50x | €174.08 Million | €351.56 Million | ▲ +65.1% |
| 2023 | 0.30x | €98.44 Million | €328.32 Million | ▲ +152.4% |
| 2022 | -0.57x | €-91.32 Million | €159.54 Million | ▲ +49.0% |
| 2021 | -1.12x | €-116.21 Million | €103.61 Million | — |